top of page
Executive Spotlights

ReNAgade Therapeutics Secures $300 Million Series A Funding to Revolutionize RNA Medicine

Cambridge, MA, May 23, 2023 (Business Wire) -- ReNAgade Therapeutics, a cutting-edge company focused on harnessing the full potential of RNA medicines for disease correction, has successfully raised $300 million in a Series A financing round led by MPM BioImpact and F2 Ventures. Built on innovative delivery technologies and an all-RNA platform, ReNAgade aims to overcome limitations in RNA therapeutics by expanding the reach of RNA medicines to previously inaccessible tissues and cells.

Read full article here.

Recent Posts

See All

Sunnyvale, CA, May 16, 2023 (Globe Newswire) -- Dave Rosa has been named President, of Intuitive overseeing the company's core business and driving product digital and commercial excellence. Rosa is

Life Science Headlines
bottom of page